NSCLC Stage IV Clinical Trial
Official title:
An Open-label, Phase II Single Arm Trial of SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors
The treatment modality with immunotherapy has been the first-line standard treatment for advanced NSCLC. But more than 2/3 patients still develop acquired drug resistance within 5 years of immunotherapy, and more than 1/2 patients are oligoprogressive. Stereotactic body radiation therapy (SBRT) plays a growing role in the management of oligometastatic disease. This study aims to evaluate the efficacy and safety of SBRT for oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors.
Status | Recruiting |
Enrollment | 28 |
Est. completion date | April 30, 2024 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age at least 18 years; - ECOG PS 0-1; - Patients with pathologically confirmed stage IV NSCLC by tumor biopsy and/or fine-needle aspiration (AJCC the 8th Edition); - Stable Disease for at least 6 months after first line immunotherapy; - Oligoprogressive disease in 5 or fewer lesions and 3 or fewer organs; - All oligopreogressive lesion = 5cm, and intracranial lesion =3cm or 30cc; - Progressive disease would be amenable to SBRT and without indications for palliative radiotherapy in the opinion of the investigator; - Patients with a history of radiotherapy are eligible if radiotherapy administered more than 4 weeks before study entry; - Adequate organ function prior to enrollment: Adequate bone marrow function: white blood cell (WBC) count = 3.0 * 10 ^ 9/L or neutrophil count = 1.5 * 10 ^ 9/L, platelet count = 100 * 10 ^ 9/L and hemoglobin =90g/L,; Adequate hepatic function: total bilirubin, urea nitrogen and serum creatinine= 1.5 x upper limit of normal (ULN). Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) =2.0 ULN; - Life expectancy of more than 3 months; - Ability to understand and willingness to provide the informed consent and signed informed consent for the use of fresh tumor biopsies before and during the treatment; - Women of childbearing age and men must agree to use effective contraception during the trial. Exclusion Criteria: - History of another malignancy or concurrent malignancy (except for cured non-melanoma skin cancer, low-risk prostate cancer, T1/T2 glottic cancer, stage 0 or I breast cancer, non-invasive bladder cancer, cervical cancer in situ); - Positive for driver genes including EGFR, ALK, and ROS-1; - Mixed small cell with non-small cell lung cancer histology; - Malignant pleural or ascites; - Patients with brain metastasis require intracranial decompression; - Symptoms of spinal cord compression; - Severe autoimmune disease: inflammatory bowel disease (including Crohn's disease and ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Wegener's granulomatosis and related vasculitides; - Symptomatic interstitial lung disease or clinically active infectious/non-infectious pneumonitis. - History of another malignancy or concurrent malignancy; - Active infection, congestive heart failure, or any evidence of myocardial infarction, unstable angina pectoris or cardiac arrhythmia within 6 months prior to enrollment; - The patient is pregnant (confirmed by serum b-HCG if applicable) or is breastfeeding; - Mental disorders, drug abuse, and social condition that may negatively impact compliance in the investigator's opinion. |
Country | Name | City | State |
---|---|---|---|
China | Zhejiang Cancer Hospital | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Zhejiang Cancer Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progress free survival | PFS was defined from the date of enrollment to the date of disease progression | two years | |
Secondary | Overall survival | OS was defined from the date of enrollment until death by any cause or last follow-up. | two years | |
Secondary | Grade 3 or higher toxicity | Treatment-related grade 3 or higher adverse events according to CTCAE 5.0. | two years | |
Secondary | Time to new metastasis | Time to new metastasis was defined from the date of enrollment to the date of new lesion progression. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05543330 -
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04106180 -
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
|
Phase 2 | |
Recruiting |
NCT05215548 -
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT04042558 -
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
|
Phase 2 | |
Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
Recruiting |
NCT04467801 -
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
|
Phase 2 | |
Active, not recruiting |
NCT04027647 -
Phase 2 Study of Dacomitinib in NSCLC
|
Phase 2 | |
Recruiting |
NCT04768491 -
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
|
||
Not yet recruiting |
NCT04492969 -
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
|
||
Recruiting |
NCT04116918 -
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
|
||
Terminated |
NCT03411473 -
Study of AGEN1884 With Pembrolizumab in 1L NSCLC
|
Phase 2 | |
Recruiting |
NCT03564197 -
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
|
N/A | |
Not yet recruiting |
NCT06219317 -
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT04604470 -
Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
|
||
Recruiting |
NCT05132218 -
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
|
||
Not yet recruiting |
NCT04136535 -
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
|
Phase 2 | |
Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
Completed |
NCT06339554 -
Alectinib-induced Endocrine Toxicity
|
||
Active, not recruiting |
NCT04549428 -
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
|
Phase 2 | |
Recruiting |
NCT03647956 -
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
|
Phase 2 |